Cocrystal Pharma (FRA:8CC) Short Interest


FRA:8CC Cocrystal Pharma Inc FRA:8CC
22 GF Score
Price €0.89
! 3 Warning Signs
View Full Analysis

What is Cocrystal Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:8CC vs HOOK, LNAI, CYCN: Short Interest Comparison

For the Biotechnology subindustry, Cocrystal Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cocrystal Pharma Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Short Interest falls into.


FRA:8CC
22GF Score
Cocrystal Pharma Inc FRA:8CC
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cocrystal Pharma Business Description

Other Exchanges COCP:USA
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
22GF Score

Get the complete analysis for FRA:8CC

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.89
Price